Purpose:To evaluate the effect and toxicity of gemcitabine cisplatin combination in elderly patients with advanced NSCLC.Methods:32 elderly patients were treaded with Gemcitabine 1 000 mg/m 2 on day 1,8 and DDP 70 mg/m 2 on day 1. The second treatment cycle was given on day 22.Results:Each patient was given at least 2 cycle chemotherapy. All together 134 cycles were given. The overall response rate (the completed response plus partial response) was 43.8%. The main toxicity was bone marrow depression. The proportion of WHO grade 3 4 hemoglobin, leukocyte and thrombocyte decrease cycles was 7.5%, 12.7%, 23.1%, respectively.Conclusions:Gemcitabine cisplatin combination is effective and well tolerated for elderly patients with NSCLC.